A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model

World Journal of Urology
Johannes FalkeJ Alfred Witjes

Abstract

TMX-101 and TMX-202 are formulations of toll-like receptor 7 (TLR-7) agonists, under investigation for the treatment of urothelial carcinoma. Our goal was to evaluate the efficacy of intravesical instillations of TMX-101 or TMX-202 in an orthotopic bladder cancer rat model. Four groups of 14 rats received an instillation with isogenic AY-27 tumor cells on day 0, starting tumor development. On day 2 and 5, the rats were treated with an intravesical instillation of TMX-101 0.1%, TMX-202 0.38%, vehicle solution or NaCl. On day 12 the rats were sacrificed and the bladders were evaluated histopathologically. No signs of toxicity were seen. The number of tumor-positive rats was 11 of 14 (79%) in the vehicle control group and in the NaCl control group, versus 9 of 14 (64%) in the TMX-101-treated group, and 8 of 14 (57%) in the TMX-20-treated group. The difference between tumor-bearing rats in the treated and control groups was not significant (p = 0.12). Bladder weight was significantly lower for TMX-202-treated rats compared to vehicle (p = 0.005). TMX-101 and TMX-202 are TLR-7 agonists with antitumor activity. Treatment with TMX-101 and TMX-202 resulted in less tumor-bearing rats compared to vehicle or saline control groups, althoug...Continue Reading

References

Aug 7, 2003·Journal of the National Cancer Institute·Margarete SchönMichael P Schön
Aug 13, 2003·The Journal of Urology·Andreas Böhle, Sven Brandau
Mar 25, 2006·The Journal of Investigative Dermatology·Gina HadleyRobert A Moore
May 19, 2007·The Journal of Urology·Eric B SmithDouglas S Scherr
Jan 19, 2008·BJU International·Kees HendricksenJ Alfred Witjes
May 2, 2008·Current Opinion in Infectious Diseases·Eun-Kyeong Jo
Feb 17, 2009·World Journal of Urology·Martine PloegLambertus A Kiemeney
May 19, 2009·Bioconjugate Chemistry·Michael ChanDennis A Carson
Mar 27, 2010·International Journal of Urology : Official Journal of the Japanese Urological Association·Tomoko HayashiDennis A Carson
Feb 15, 2011·BJU International·Harm C ArentsenJ Alfred Witjes
Mar 23, 2011·The Journal of Urology·Cherifa AyariYves Fradet
Mar 17, 2012·European Urology·Hussain M AlnajjarNicholas A Watkin
Jul 6, 2013·European Urology·Marko BabjukUNKNOWN European Association of Urology
Feb 5, 2014·Nature Reviews. Urology·Gil Redelman-SidiBernard H Bochner
Jun 19, 2016·The Journal of Urology·Sam S ChangJames M McKiernan
Jul 28, 2016·The Journal of Urology·Nicholas M DoninKarim Chamie

❮ Previous
Next ❯

Citations

Sep 1, 2018·World Journal of Urology·Morgan Rouprêt
Mar 24, 2020·European Journal of Medicinal Chemistry·Cindy PatinoteCarine Deleuze-Masquéfa

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02808143
NCT02324582
NCT02792192
NCT02844816
NCT01687244
NCT02138734

Software Mentioned

GraphPad Prism
GraphPad
SPSS Statistics

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.